Immunogenicity and safety of tixagevimab-cilgavimab for COVID-19 pre-exposure prophylaxis in immunocompromised 20 to <40 kg children and adolescents: A pilot, prospective, open-labeled study

We evaluated the immunogenicity of 300 mg Tixagevimab-Cilgavimab in immunocompromised children and adolescents who weighed 20 to >40 kg. Six to 18-year-old participants were divided into two groups by body weight and received 300 mg (20 to 

Saved in:
Bibliographic Details
Published in:Human vaccines & immunotherapeutics 2024-12, Vol.20 (1), p.2428011
Main Authors: Buaboonnam, Jassada, Rungmaitree, Supattra, Piyaphanee, Nuntawan, Charuvanij, Sirirat, Pitisuttithum, Onsiri, Copeland, Katherine, Pheerapanyawaranun, Chatkamol, Jansarikit, Laddawan, Niyomnaitham, Suvimol, Chokephaibulkit, Kulkanya
Format: Article
Language:English
Subjects:
Adolescent
adolescents
Antibodies, Monoclonal, Humanized - administration & dosage
Antibodies, Monoclonal, Humanized - adverse effects
Antibodies, Monoclonal, Humanized - immunology
Antibodies, Monoclonal, Humanized - therapeutic use
Antibodies, Neutralizing - blood
Antibodies, Viral - blood
BNT162 Vaccine - immunology
Body Weight
Child
children
Coronavirus
COVID-19
COVID-19 - immunology
COVID-19 - prevention & control
Female
Humans
immunocompromised
Immunocompromised Host
Immunoglobulin G - blood
long-acting antibody
Male
monoclonal antibody
Pilot Projects
pre-exposure prophylaxis
Pre-Exposure Prophylaxis - methods
Prospective Studies
SARS-CoV-2 - immunology
Thailand
Tixagevimab-cilgavimab
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated the immunogenicity of 300 mg Tixagevimab-Cilgavimab in immunocompromised children and adolescents who weighed 20 to >40 kg. Six to 18-year-old participants were divided into two groups by body weight and received 300 mg (20 to 
ISSN:2164-5515
2164-554X
2164-554X
DOI:10.1080/21645515.2024.2428011